Results 221 to 230 of about 76,116 (300)

Case Report: Making room for radicality: balancing liver reserve and oncologic clearance in hilar cholangiocarcinoma through portal vein embolisation. [PDF]

Front Surg
Lee EJH, Tan ZS, Azman A, Azzaki Zainal I, Abdul Muien MZ, Chik I.   +5 more
europepmc   +1 more source

Clinical Outcomes of Multi‐Hole Covered Self‐Expandable Metal Stents for Malignant Distal Biliary Obstruction: A Retrospective Comparative Study With an Exploratory Evaluation of 6‐mm Devices

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Covered self‐expandable metal stents (CSEMS) are widely used for malignant distal biliary obstruction (MDBO), but cholecystitis, post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), stent migration, and recurrent biliary obstruction (RBO) remain clinically important limitations.
Akinobu Koiwai, Yuki Miyashita, Nana Inomata, Takehito Ito, Morihisa Hirota, Kennichi Satoh   +5 more
wiley   +1 more source

Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. [PDF]

Int J Mol Sci
Qi H, Pan J, Wu H.
europepmc   +1 more source

Efficacy and Safety of Endoscopic Ultrasound‐Guided Biliary Drainage in the Management of Malignant Hilar Biliary Obstruction: A Multicenter Retrospective Cohort Study

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Malignant hilar biliary obstruction (MHBO) remains challenging for biliary decompression. Although endoscopic ultrasound‐guided biliary drainage (EUS‐BD) has emerged as an alternative to endoscopic retrograde cholangiopancreatography‐guided BD (ERCP‐BD), evidence regarding EUS‐BD for MHBO is limited. Aims To evaluate the efficacy and safety of
Takuji Iwashita, Kazuki Hayashi, Michihiro Yoshida, Reiko Yamada, Koichiro Matsuda, Shinichi Morita, Tadahisa Inoue, Kazuhiko Shioji, Keisuke Iwata, Akinori Maruta, Nobuhiko Hayashi, Masaaki Yano, Ichiro Yasuda   +12 more
wiley   +1 more source

Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma. [PDF]

ESMO Open
Hsu CC, Yeh KY, Chang CF, Wu CF, Kou HW, Chen YF, Chen MY, Hsu JT, Yeh CN, Wu CE, Huang WK, Ku CH, Lan CC, Hsieh CL, Hsu YW, Hsieh CH, Chang LL, Huang SC, Chen TC, Chen JS, Hung YS, Chou WC.   +21 more
europepmc   +1 more source

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Risk of Long-Term Survival After Hepatic Resection for Hepatocellular and Intrahepatic Cholangiocarcinoma: Population-Based Analysis in Korea. [PDF]

J Korean Med Sci
Lee JM, Kim SJ, Yoo T, Cho W.
europepmc   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

From infection to cholangiocarcinoma: Why opisthorchiids break these rules. [PDF]

One Health
Heneberg P.
europepmc   +1 more source

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients

International Journal of Cancer, Volume 159, Issue 7, Page 1829-1843, 1 October 2026.
Long non‐coding RNAs (lncRNAs) signatures are promising cancer biomarkers, since their dysregulation in tumors is reflected in body fluids. In this study, next‐generation sequencing, bioinformatics, and gene expression data were combined to investigate an lncRNA signature linked specifically to the cancer‐promoting YAP in several cancer types ...
Fabian Rose, Nada El‐Ekiaby, Lilija Wehling, Sofia Maria Elisabeth Weiler, Jennifer Schmitt, Marcell Tóth, Fabiola Pedrini, Amruta Damle‐Vartak, Carsten Sticht, Rossella Pellegrino, Injie Omar Fawzy, Merna Hatem Mohamed Hamad, Mohamed Negm, Dina Omar, Hossam Eldeen Soliman, Gamal Esmat, Thomas Longerich, Thomas Illig, Bruno Christian Köhler, Anna Saborowski, Heike Bantel, Arndt Vogel, Peter Schirmacher, Ahmed Ihab Abdelaziz, Kai Breuhahn   +24 more
wiley   +1 more source